Related Experiment Video
Updated: Jul 19, 2026
09:57
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
12.0K
MCC950 attenuates plasma cell mastitis in an MDSC-dependent manner
Xiaowei Sun1, Junchen Hou1, Tianyi Ni2
1Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, Jiangsu, PR China.
International Immunopharmacology
|March 9, 2024
Summary
NLRP3 inflammasome inhibition with MCC950 effectively treats plasma cell mastitis (PCM) by reducing inflammation and enhancing myeloid-derived suppressor cells (MDSCs). This offers a potential non-surgical therapeutic approach for PCM.
Area of Science:
- Immunology
- Inflammation research
- Pharmacology
Background:
- Plasma cell mastitis (PCM) is an inflammatory condition lacking non-invasive treatments.
- The NLRP3 inflammasome is implicated in inflammatory diseases, but its role in PCM is unknown.
Purpose of the Study:
- To investigate the role of NLRP3 inflammasome in PCM pathogenesis.
- To evaluate the therapeutic potential of NLRP3 inhibition for PCM.
Main Methods:
- Established a murine model of PCM.
- Administered MCC950, an NLRP3 inhibitor, to PCM mice.
- Assessed inflammation, plasma cell infiltration, pro-inflammatory cytokines, and myeloid-derived suppressor cell (MDSC) function.
Main Results:
- NLRP3 was significantly upregulated in PCM tissues.
- MCC950 treatment reduced plasma cell infiltration and pro-inflammatory cytokines (IL-1β, TNF-α, IL-2, IL-6).
- MCC950 enhanced MDSC function, which was crucial for its therapeutic effect.
Conclusions:
- NLRP3 inflammasome plays a key role in PCM.
- MCC950 ameliorates PCM by augmenting MDSCs, offering a potential non-surgical treatment.
- This study highlights pharmacological agents targeting NLRP3 for PCM therapy.
